IGHV mutational status and the choice of first-line therapy for patients with chronic lymphocytic leukaemia

Hematology in Clinical Practice · Published 2022-05-20 · DOI 10.5603/hcp.2022.0003

Authors being retrieved — see the publisher record. https://doi.org/10.5603/hcp.2022.0003

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2022

Related articles

The effect of bone marrow reticulin fibrosis degree at diagnosis on the success of intensive and reduced Intensity Induction therapy in de novo AML patients: retrospective single-center study · Hematology in Clinical Practice · 2025 · Same journal
Therapeutic options in high-risk myelodysplastic syndrome · Hematology in Clinical Practice · 2023 · Same journal
The use of midostaurin in aggressive systemic mastocytosis (ASM) with the c-KIT D816V mutation within The Emergency Access to Drug Technologies Programme · Hematology in Clinical Practice · 2021 · Same journal
Cutaneous Rosai–Dorfman disease: a comprehensive literature review and two case reports · Hematology in Clinical Practice · 2025 · Same journal
Burkitt-like lymphoma with 11q aberration mimicking appendicitis in a young man — a diagnostic and therapeutic challenge · Hematology in Clinical Practice · 2022 · Same journal
Coexistence of chronic lymphocytic leukemia and NK/T lymphoma of the nasopharynx in a patient treated with ibrutinib · Hematology in Clinical Practice · 2023 · Same journal
Large granular lymphocyte leukemias — current opinions on diagnosis and management · Hematology in Clinical Practice · 2025 · Same journal
Osteosclerotic bone lesions in chronic lymphocytic leukemia — case report and literature review · Hematology in Clinical Practice · 2025 · Same journal
Pulmonary embolism after anti-SARS-CoV-2 vaccines in two female patients · Hematology in Clinical Practice · 2023 · Same journal
Bispecific antibodies in the treatment of follicular lymphoma · Hematology in Clinical Practice · 2023 · Same journal